Agreement of amyloid PET and CSF biomarkers for Alzheimer’s disease on Lumipulse

Daniel Alcolea¹,², Jordi Pegueroles¹,², Laia Muñoz¹,², Valle Camacho³, Diego López-Mora³, Alejandro Fernández-León³, Nathalie Le Bastard⁴, Els Huyck⁴, Alicia Nadal⁵, Verónica Olmedo⁵, Frederic Sampedro⁶, Victor Montal¹,², Eduard Vilaplana¹,², Jordi Clarimon¹,², Rafael Blesa¹,², Juan Fortea¹,² & Alberto Lleó¹,²

¹Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau - Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Barcelona, Spain
²Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, CIBERNED, Madrid, Spain
³Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
⁴Fujirebio Europe N.V., Gent, Belgium
⁵Fujirebio Iberia, S.L., Barcelona, Spain

Correspondence
Daniel Alcolea, Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret 167, 08025 Barcelona, Spain. Tel: +34935565986; Fax: +34935568604; E-mail: dalcolea@santpau.cat

Funding Information
This study was supported by CIBERNED and Instituto de Salud Carlos III PI13/01532 and PI16/01825 to R.B.; PI14/01561 and PI17/01895 to A.L; PI14/01126 and PI17/01019 to J.F., PI18/00435 to D.A., jointly funded by Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea, “Una manera de hacer Europa”. This work was also supported by Generalitat de Catalunya (2017-SGR-547, SLT006/17/125 to D.A., SLT006/17/95 to E.V. and SLT006/17/119 to J.F.) and “Marató TV3” foundation grants 20141210 to J.F., 20161431 to R.B. and 20142610 to A.L. All kits and reagents to perform cerebrospinal fluid analyses in this study were provided by Fujirebio Europe. La Caixa Foundation.

Received: 10 May 2019; Revised: 26 July 2019; Accepted: 2 August 2019

Annals of Clinical and Translational Neurology 2019; 6(9): 1815–1824
doi: 10.1002/acn3.50873

Abstract

Objective: To determine the cutoffs that optimized the agreement between ¹⁸F-Florbetapir positron emission tomography (PET) and Aβ1-42, Aβ1-40, tTau, pTau and their ratios measured in cerebrospinal fluid (CSF) on the LUMIPULSE G600II instrument, we quantified the levels of these four biomarkers in 94 CSF samples from participants of the Sant Pau Initiative on Neurodegeneration (SPIN cohort) using the Lumipulse G System with available ¹⁸F-Florbetapir imaging. Methods: Participants had mild cognitive impairment (n = 35), AD dementia (n = 12), other dementias or neurodegenerative diseases (n = 41), or were cognitively normal controls (n = 6). Levels of Aβ1-42 were standardized to certified reference material. Amyloid scans were assessed visually and through automated quantification. We determined the cutoffs of CSF biomarkers that optimized their agreement with ¹⁸F-Florbetapir PET and evaluated concordance between markers of the amyloid category. Results: Aβ1-42, tTau and pTau (but not Aβ1-40) and the ratios with Aβ1-42 had good diagnostic agreement with ¹⁸F-Florbetapir PET. As a marker of amyloid pathology, the Aβ1-42/Aβ1-40 ratio had higher agreement and better correlation with amyloid PET than Aβ1-42 alone. Interpretation: CSF biomarkers measured with the Lumipulse G System show good agreement with amyloid imaging in a clinical setting with heterogeneous presentations of neurological disorders. Combination of Aβ1-42 with Aβ1-40 increases the agreement between markers of amyloid pathology.
Introduction

Advances in the field of biomarkers have pushed forward a redefinition of Alzheimer’s disease (AD) as a biological construct.1 Under this definition, the ATN classification system recognizes three general groups of biomarkers for AD: biomarkers of β-amyloid plaques (A), biomarkers of fibrillar tau (T) and biomarkers of neurodegeneration or neuronal injury (N).1 These categories can be assessed by using different modalities, but those that are more widely implemented are cerebrospinal fluid (CSF) biomarkers and imaging techniques. Amyloid positron emission tomography (PET), CSF Aβ1-42 and the ratio Aβ1-42/Aβ1-40 correspond to the “A” category, Tau PET and CSF pTau to the “T” category, whereas 18F-Fluorodeoxyglucose-PET, anatomical MRI and tTau are considered markers of the “N” category.1 Within the “A” category, the concordance between CSF Aβ1-42 and amyloid PET imaging is high, but not perfect.2–6 In fact, the Aβ1-42/Aβ1-40 ratio has shown to have better agreement with amyloid PET imaging compared to levels of Aβ1-42 alone.4,7–9

In recent years, fully automated platforms have been developed for the analysis of CSF biomarkers. Recently, four CSF analytes (Aβ1-42, Aβ1-40, tTau and pTau) have been implemented on the fully automated Lumipulse G System, but there are no validated cutoffs for these four AD CSF biomarkers using this platform. Our aims were to determine for the first time the cutoffs that optimized the agreement between 18F-Florbetapir PET and Aβ1-42, Aβ1-40, tTau, pTau and their ratios measured in CSF on the LUMIPULSE G600II instrument, and to evaluate the concordance between markers of the amyloid category.

Methods

Study participants

We included 94 participants from the Sant Pau Initiative on Neurodegeneration (SPIN cohort) recruited between November 2013 and September 2017 who had available CSF samples and 18F-Florbetapir PET imaging (Table 1). The SPIN cohort is a multimodal research cohort for biomarker discovery and validation that includes participants with different neurodegenerative dementias, mild cognitive impairment and cognitively normal controls. All participants receive an extensive neurological and neuropsychological evaluation and undergo structural 3T brain MRI, blood extraction, and lumbar puncture for CSF biomarkers. A subset of participants also receives molecular imaging such as 18F-Fluorodeoxyglucose-PET, amyloid and/or Tau PET. More information on the SPIN cohort can be found at https://santpaumemoryunit.com/.

Table 1. Clinical and demographic characteristics of all participants and based on visual amyloid PET status.

|                                | All participants | Amyloid positive | Amyloid negative | P value |
|--------------------------------|------------------|------------------|------------------|---------|
| n (%)                          | 94 (100%)        | 59 (63%)         | 35 (37%)         | –       |
| Age, years                     | 73.0 (7.6)       | 73.5 (7)         | 72.1 (8.5)       | 0.405*  |
| Sex, female/male (% female)    | 50/44 (53%)      | 32/27 (54%)      | 18/17 (51%)      | 0.960†  |
| APOEε4 +/+ (% +)               | 56/37 (60%)      | 30/28 (52%)      | 7/28 (20%)       | 0.004†  |
| MMSE score                     | 24.7 (4.1)       | 24.1 (4.3)       | 25.7 (3.6)       | 0.052*  |
| Time difference between amyloid PET and lumbar puncture, days | 152 (86) | 151 (78) | 156 (100) | 0.792* |
| Clinical diagnosis, n (%)      |                  |                  |                  | 0.067†  |
| Cognitively normal             | 6 (100%)         | 3 (50%)          | 3 (50%)          | –       |
| Mild cognitive impairment      | 35 (100%)        | 23 (66%)         | 12 (34%)         | –       |
| AD dementia                    | 12 (100%)        | 11 (92%)         | 1 (8%)           | –       |
| Dementia with Lewy bodies      | 30 (100%)        | 18 (60%)         | 12 (40%)         | –       |
| Frontotemporal dementia        | 9 (100%)         | 3 (33%)          | 6 (67%)          | –       |
| Other diagnoses                | 2 (100%)         | 1 (50%)          | 1 (50%)          | –       |
| CSF biomarkers                 |                  |                  |                  | –       |
| Aβ1-42, pg/mL                  | 745 (379)        | 608 (213)        | 985 (474)        | <0.001* |
| Aβ1-40, pg/mL                  | 12252 (3944)     | 12782 (3954)     | 11360 (3816)     | 0.089*  |
| tTau, pg/mL                    | 566 (363)        | 667 (375)        | 397 (273)        | <0.001* |
| pTau, pg/mL                    | 93 (71)          | 114 (71)         | 58 (58)          | –       |
| Aβ1-42/Aβ1-40                  | 0.064 (0.028)    | 0.049 (0.015)    | 0.088 (0.027)    | <0.001* |
| tTau/Aβ1-42                    | 0.95 (0.76)      | 1.17 (0.63)      | 0.57 (0.81)      | <0.001* |
| pTau/Aβ1-42                    | 0.16 (0.15)      | 0.20 (0.12)      | 0.09 (0.16)      | <0.001* |

Unless otherwise specified, results are presented as mean (standard deviation). MMSE, Mini-mental state examination; AD, Alzheimer’s disease; CSF, cerebrospinal fluid; PET, positron emission tomography. P-values were calculated by comparing amyloid-positive and amyloid-negative participants using Welch two-sample t-test (*) or Fisher’s exact test (†).
our research/spin-cohort (Alcolea et al., submitted). All participants gave written consent, and the ethics committee of Hospital Sant Pau approved all procedures included in this study.

**CSF samples acquisition and analysis**

CSF samples were collected in 10 mL polypropylene tubes (Sarstedt, Ref#62.610.018) and transferred to the Sant Pau Memory Unit’s laboratory where they were processed within the first 2 h after acquisition. After centrifugation (2000g × 10 min, 4°C), volumes of 0.5 mL of CSF were aliquoted into polypropylene tubes (Sarstedt, Ref#72.694.007) and stored at −80°C until analysis.

On the day of the analysis, samples were thawed at room temperature and the tubes were vortexed for 5–10 sec. To avoid the effect of multiple freeze-thaw cycles, aliquots used in this study had not been thawed before. Aβ1-42, Aβ1-40, tTau and pTau were quantified directly from the storage tubes containing 0.5 mL of CSF using the Lumipulse G β-Amyloid 1-42, β-Amyloid 1-40, Total Tau and pTau 181 assays on LUMIPULSE G600II automated platform (Fujirebio) and following the manufacturer’s instructions. We used an adapter to fit the tubes in the equipment. We used the same batch of reagents for each biomarker throughout the study, and for each sample, we measured all four analytes from the same aliquot and in the same run. The platform was configured to start the analysis with Aβ1-42, followed by Aβ1-40, tTau and pTau. Buffer-based quality control testing was performed at the beginning of each test day to ensure that all measured values of each control level (low, medium and high) were within the target ranges.

The results of the Lumipulse G β-Amyloid 1-42 presented in this study have been standardized according to certified reference material developed by the International Federation of Clinical Chemistry and Laboratory Medicine as recommended by their working group for CSF proteins. Briefly, values of the calibration standards of the LUMIPULSE G600II were adapted to the certified reference material resulting in an adjustment of concentrations that was linearly proportional throughout the range. The aim of standardization to certified reference material is to harmonize immunoassays of Aβ1-42 to make results comparable across different platforms.

Aβ1-42, Aβ1-40, tTau and pTau levels in CSF from participants of this study had been measured previously using other immunoassays (INNOTEST β-AMYLOID[1-42], INNOTEST hTAU Ag, and INNOTEST PHOSPHO-TAU[181P], Fujirebio Europe; and High Sensitivity Human Amyloid β40, Merck-Millipore), and these results were available in our database for their comparison with the LUMIPULSE analyses.

The personnel involved in the CSF analyses for this study were blinded to the clinical diagnosis and to previous biomarker determinations.

**Amyloid-PET imaging acquisition, visual assessment and quantitative analysis**

All participants underwent amyloid PET imaging with 18F-Florbetapir as described elsewhere. PET data were acquired using a Philips Gemini TF scan 50 min after injection of 370mBq of 18F-Florbetapir. After obtaining the transmission data, brain PET dynamic acquisition was performed (2 × 5 min frames). The reconstruction method was iterative (LOR RAMBLA, three iterations and 33 subsets) with a 128 × 128 image size, 2 mm pixel size and slice thickness.

Three expert readers (V.C., D.L-M. and A.F-L.) blind to clinical diagnosis and to CSF biomarkers visually rated all PET scans. Following manufacturer’s protocol, scans were classified as “positive” when one or more areas showed increased cortical gray matter signal resulting in reduced or absent contrast between gray matter and white matter. Scans were classified as “negative” when the contrast between gray matter and white matter was clear. Final classification as “positive” or “negative” was decided upon agreement of at least two of three readers. Mean inter-reader overall agreement was 88.4% (Min = 87.0%, Max = 90.2%).

We also quantified amyloid deposition. Each participant’s PET scan was spatially normalized to a MNI152 18F-Florbetapir template using a linear and nonlinear transformation. Mean 18F-Florbetapir uptake was measured across frontal, lateral parietal, lateral temporal and anterior/posterior cingulate. Then, the 18F-Florbetapir standardized uptake value ratio (SUVR) map was extracted using the whole cerebellum as reference. The PET scans of five participants were not suitable for 18F-Florbetapir quantification and excluded of quantitative analyses.

**Statistical analysis**

We performed receiver operating characteristic (ROC) analysis for Aβ1-42, Aβ1-40, tTau, pTau and the ratios Aβ1-42/Aβ1-40, tTau/Aβ1-42 and pTau/Aβ1-42 to calculate areas under the curve (AUC) with 95% confidence intervals (DeLong). We compared ROC curves by two-sided bootstrapping with 2000 replications. For biomarkers and ratios that showed AUC higher than 0.70, we determined positive percent agreement (PPA or sensitivity) and negative percent agreement (NPA or specificity) and calculated optimal cutoffs maximizing their Youden J index (PPA + NPA − 1). We calculated overall percent agreement (OPA) between CSF biomarker cutoffs and amyloid PET visual interpretation as the sum of...
participants classified as “positive” or as “negative” by both modalities over the total number of participants. We also analyzed the correlation of CSF biomarkers with global amyloid accumulation by fitting quadratic models and calculated the agreement of CSF biomarkers cutoffs with the PET scans quantification status applying a previously described SUVR cutoff of 1.11.17 Level of significance was set at $\alpha = 0.05$. We used Analyse-it® statistical software for the selection of optimal cutoffs and packages “car” (v.3.0-3, Fox&Weisberg 2019), “pROC” (v.1.15.0, Robin et al 2011), “grid” (R core team 2019) and “ggplot2” (v.3.1.1, Wickham 2016) as implemented in R statistical software (v 3.6.0) for plots and statistical analyses.

## Results

### Study participants

We included 94 participants in the study. Table 1 summarizes demographic characteristics and biomarker results. There were no differences in age or sex between both groups. As expected, the amyloid–positive group had a higher proportion of APOEε4 carriers compared to the amyloid–negative group (52% and 20%, respectively; $P = 0.004$).

### Quantification of Aβ1-42, Aβ1-40, tTau and pTau concentrations on the LUMIPULSE G600II

We measured Aβ1-42, Aβ1-40, tTau and pTau levels simultaneously on the Lumipulse G System. Their levels in the overall study population ranged from 315 to 2280 pg/mL for Aβ1-42, 4585 to 25925 pg/mL for Aβ1-40, 141 to 1902 pg/mL for tTau, and 18 to 340 pg/mL for pTau.

The analyses were divided over three calibration runs on the LUMIPULSE G600II, and the calibration status was valid for all samples. Mean interassay coefficients of variation are displayed in Figure S1.

Most CSF samples included in this study had previously been analyzed using other immunoassays, and their results were available in our database. Although these historic results were obtained in the context of routine clinical assessment by using different batches, and therefore a side-to-side precision analysis could not be performed, we explored their correlation with the Lumipulse G quantifications. The Lumipulse G assays for Aβ1-42, tTau and pTau showed very high correlation with values previously measured with Fujirebio’s INNOTEST ELISA (Pearson’s $r$ of 0.94, 0.95 and 0.95, respectively, all $P < 0.001$). The Lumipulse G assay for Aβ1-40 showed moderate correlation with values measured with Merck-Millipore’s ELISA (Pearson’s $r$ of 0.76, $P < 0.001$). On the Lumipulse G system, tTau and pTau were highly correlated (Pearson’s $r$ of 0.98, $P < 0.001$).

### Agreement between 18F-Florbetapir visual status and CSF biomarkers

As displayed in Figure 1A, of individual biomarkers, tTau and pTau had the highest accuracy and showed AUC of 0.80 (95%CI 0.70–0.89, $P < 0.001$) and 0.84 (95%CI 0.75–0.93, $P < 0.001$), respectively. Aβ1-42 had fair accuracy with an AUC of 0.76 (95%CI 0.65–0.86, $P < 0.001$) and Aβ1-40 alone was not useful for the detection of the visual status of amyloid scans (AUC 0.59; 95%CI 0.47–0.71, $P = 0.134$).

Figure 1B shows that the combination of Aβ1-42 with a second analyte resulted in significant increases of accuracy. The AUC of Aβ1-42/Aβ1-40 was 0.86 (95%CI 0.77–0.96, $P < 0.001$), higher than that of Aβ1-42 alone ($D = -2.5; P = 0.01$) or Aβ1-40 alone ($D = -4.0; P < 0.001$). tTau/Aβ1-42 had an AUC of 0.87 (95%CI 0.78–0.95, $P < 0.001$), higher than that of tTau ($D = -2.2; P = 0.03$), and pTau/Aβ1-42 had an AUC of 0.88 (95%CI 0.79–0.97, $P < 0.001$), higher than that of pTau alone ($D = -1.9; P = 0.05$). There were no significant differences in the AUC of the three ratios, and combining a third biomarker in the ratios did not improve their accuracy (data not shown).

### CSF biomarker cutoffs based on visual interpretation of amyloid status

For those biomarkers and ratios that showed AUC higher than 0.70, we used ROC analysis to obtain PPA, NPA and OPA for all possible cutoffs. As displayed in Figure 2, in the case of single biomarkers, Aβ1-42, tTau and pTau, the selection was based on clear Youden peaks at 916, 456 and 63 pg/mL, respectively. For the ratios Aβ1-42/Aβ1-40, tTau/Aβ1-42 and pTau/Aβ1-42, plots showed plateau stages indicating that a wide range of cutoffs yielded similar Youden indices. Best cutoffs for ratios were 0.062 for Aβ1-42/Aβ1-40, 0.62 for tTau/Aβ1-42, and 0.068 for pTau/Aβ1-42.

Figure 3 displays the agreement between visual status of 18F-Florbetapir and CSF biomarker cutoffs. For Aβ1-42, tTau and pTau, the OPA values between visual status and CSF biomarkers status were 79%, 78% and 81%, respectively. The ratio of Aβ1-42 with Aβ1-40, tTau and pTau increased the OPA to 84%, 82% and 88%, respectively.

### Markers of amyloid and importance of assessing a second biomarker

Within each CSF biomarker status, the proportion of positive amyloid scans varied when a second biomarker or ratio was taken into account. Figure S2 shows the
proportion of positive amyloid scans within each combination of two CSF biomarkers or ratios, and illustrates the importance of considering a second biomarker. Of all participants with low CSF levels of Aβ1-42, regardless of the Aβ1-42/Aβ1-40 ratio status, 77% (56 out of 73) had a positive amyloid scan. This proportion increased to 87% (52 out of 60) within this group when the Aβ1-42/Aβ1-40 ratio was also low but decreased to 31% (four out of 13) when the Aβ1-42/Aβ1-40 ratio was high. In the group of participants with high CSF levels of Aβ1-42, the impact of considering the Aβ1-42/Aβ1-40 status had no effect, as in all participants within this group the Aβ1-42/Aβ1-40 ratio was also high. These results highlight the importance of using the Aβ1-42/Aβ1-40 ratio over Aβ1-42 alone in the assessment of brain amyloidosis, especially in patients with low CSF levels of Aβ1-42.

Agreement of CSF cutoffs with amyloid quantification

We next processed amyloid PET scans to obtain quantification values of amyloid deposition. In our study, the previously validated SUVR value of 1.11 showed 83% PPA, 76% NPA, and 81% OPA with visual classification. As displayed in Figure 4, scans that were divergently classified as “negative” or “positive” by one of the three raters showed intermediate SUVR values compared to scans that were unanimously classified.

As seen in Figure 5, the agreement of CSF cutoffs with amyloid PET quantification was similar to that with visual classification for all biomarkers. We studied the correlation between each CSF biomarker and global amyloid accumulation by fitting quadratic models. In these models, the adjusted coefficients of determination (R²) were higher for all ratios compared to individual biomarkers. The combination of Aβ1-42 with Aβ1-40 increased the R² value to 0.44 (P < 0.001), indicating that this ratio reflects the amyloid deposition better than Aβ1-42 alone. Stratified analysis by 18F-Florbetapir visual status showed lower R² values for all biomarkers, which suggests that the correlation observed between CSF biomarkers and amyloid PET quantification is partially mediated by an amyloid-status effect. In this stratified analysis, the highest correlation of SUVR values was found with the Aβ1-42/Aβ1-40 ratio in the amyloid-negative group (R² = 0.42; P < 0.001).

Discussion

In our study, we determined cutoffs for four CSF biomarkers for AD (Aβ1-42, Aβ1-40, tTau and pTau) and their ratios measured on the fully automated LUMIPULSE G600II platform to optimize their concordance with 18F-Florbetapir PET. We calibrated Aβ1-42 levels to certified reference material, recently developed to harmonize immunoassays across different platforms, and found
that the ratios $A\beta_{1-42}/A\beta_{1-40}$, tTau/$A\beta_{1-42}$ and pTau/$A\beta_{1-42}$ had better diagnostic agreement with visual assessment of amyloid scans than single biomarkers. As a marker of amyloid pathology, the $A\beta_{1-42}/A\beta_{1-40}$ ratio had higher agreement with amyloid PET visual status and showed better correlation with amyloid load quantification compared to $A\beta_{1-42}$ alone.

The agreement between amyloid imaging and AD CSF biomarkers has previously been studied by using other automated immunoassays.\textsuperscript{3,4,8} Our results are in line with previous studies showing a good overall agreement between amyloid imaging and AD CSF biomarkers, higher for ratios than for single analytes.\textsuperscript{3,4} However, specific cutoff points for CSF biomarkers differ between these studies, and several methodological differences can explain these discrepancies. First, preanalytical conditions, such as the type of collection and storage tubes, are different between studies, and these factors are known to have a great impact on the absolute values of CSF biomarkers, especially for $A\beta_{1-42}$.\textsuperscript{18,19} Second, some analytical particularities for each immunoassay and platform used in these studies (specificity of the antibodies, time of incubation) result in diverse CSF biomarker measures. Calibration of all automated platforms to certified reference material, currently underway, will minimize this issue in the future. Likewise, differences in the affinity of PET radiotracers ($^{11}$C-Pittsburg compound B, $^{18}$F-Flutemetamol or


**Figure 3.** Agreement of visual amyloid status with single and combined CSF biomarkers. Panels A, B and C display scatterplots of CSF biomarker levels. Dashed lines indicate cutoffs that yielded maximum Youden J Index in the receiver operating characteristic analysis for each biomarker or ratio. PPA, Positive Percent Agreement; NPA, Negative Percent Agreement; OPA, Overall Percent Agreement.

**Figure 4.** Agreement between raters’ visual classification and amyloid quantification. OPA, Overall Percent Agreement; SUVR, Standardized Uptake Value Ratio. Panel A shows the agreement between amyloid quantification and rater’s individual and global visual assessments. Panel B shows the agreement between amyloid quantification and visual assessment stratified by the number of raters that assessed scans as positive.

$^{18}$F-Florbetapir) can lead to disparities in the selection of cutoffs. Third, the composition of the populations was not the same across studies. Schindler et al. analyzed data from community-dwelling volunteers, whereas Janelidze et al. obtained their results from patients with mild cognitive impairment and subjective cognitive decline from the BioFINDER cohort. Hansson et al. studied CSF of participants from ADNI and BioFINDER cohorts, that included cognitively normal volunteers, patients with mild cognitive impairment and patients with AD dementia. In our study, we additionally included patients with other dementias or neurodegenerative diseases, which might reflect more realistically the application of biomarkers in daily clinical practice. The cutoffs in our study were selected by maximization of Youden J index. This approach balances sensitivity and specificity and is equivalent to maximize accuracy for a pre-test disease prevalence of 50%. However, other strategies might be useful in certain clinical scenarios. For instance, for screening purposes, it might be helpful to apply cutoffs with high sensitivity, even when their specificity is lower. For patients with clinically challenging diagnoses or in clinical trials, however, high specificity might be preferable. Other possible approaches include the sequential application of biomarker cutoffs.

The LUMIPULSE G600II has incorporated the possibility of measuring CSF levels of $A\beta_{1-40}$. In previous studies, and ours, this biomarker alone was not useful for the detection of brain amyloid. Both $A\beta_{1-42}$ and the
Aβ1-42/Aβ1-40 ratio are included in the “A” category of the ATN classification system together with amyloid PET, but in line with other studies, we found that the Aβ1-42/Aβ1-40 ratio had better agreement with visual amyloid status and higher correlation with brain amyloid quantification. Our results are in line with previous literature that suggests that the use of the Aβ1-42/Aβ1-40 ratio could compensate individual differences in amyloid precursor protein processing that otherwise might lead to false positive or false negative Aβ1-42 CSF levels.
information adds to the fact that using the Aβ1-42/Aβ1-40 ratio has proven to partially mitigate the effect of some preanalytical confounders that have been described to alter the results of amyloid levels. Altogether, our data suggest that the use of the Aβ1-42/Aβ1-40 ratio would be more reliable in clinical practice than Aβ1-42 alone as a marker of amyloidosis and that this combination should be used in routine.

The main strength of our study is that four AD CSF biomarkers (Aβ1-42, Aβ1-40, tTau and pTau) measured simultaneously with the automated Lumipulse G System were compared for the first time to 18F-Florbetapir PET to calculate amyloid-based cutoffs. In addition, this is, to our knowledge, the first study to present Aβ1-42 levels that have been standardized to certified reference material, recently developed to harmonize immunoassays across different platforms. Standardized values will make our study more easily comparable to future studies. Moreover, to avoid possible sources of variability, we followed homogeneous CSF preanalytical and analytical procedures and used the same batch of reagents for all measurements. Also, the inclusion of participants with neurodegenerative diseases outside the AD spectrum provides a more realistic application of biomarkers in daily clinical practice.

However, we are aware of some limitations. We did not test the effect that deviations from our preanalytical protocol would have on the final cutoffs, and therefore, the cutoffs that we report should be taken cautiously under other operating procedures. Some of the clinical categories in our study included a small number of participants. Although we used amyloid positivity/negativity as the gold standard in our study, the composition of the sample in terms of clinical diagnosis might be relevant for the interpretation and applicability of our results. Additionally, only very few participants had additional Tau imaging and/or 18F-Fluorodeoxyglucose-PET, and we could not compare the agreement of CSF pTau and tTau with molecular imaging markers of the “T” and the “N” categories of the ATN classification. Likewise, as participants in this study are part of a living cohort, neuropathological confirmation is not available at this moment.

In this study, we found that the Aβ1-42 ratios to Aβ1-40, tTau and pTau in CSF show a good agreement with amyloid visual status and that the Aβ1-42/Aβ1-40 ratio had better correlation with the amount of amyloid burden compared to Aβ1-42 alone. The understanding of the agreement between CSF biomarkers and amyloid imaging is crucial to identify situations in which these two modalities might not be interchangeable. This information has to be taken into consideration both in the diagnostic assessment in clinical practice and in the selection of participants in clinical trials.

**Acknowledgment**

We are grateful to all participants in the study and to all the members of the clinical team that were involved in the selection and assessment of participants.

**Conflict of Interest**

D.A. participated in advisory boards from Fujirebio-Europe and received speaker honoraria from Fujirebio-Europe, Nutricia and from Krka Farmacéutica S.L. R.B. participated in advisory boards from Lilly and Nutricia, and he received speaker honoraria and travel funding from Novartis and Nutricia. A.L. participated in advisory boards from Fujirebio-Europe, Nutricia, Biogen, and received speaker honoraria from Lilly. N.L.B. and E.H. are employed by Fujirebio Europe. N.V. A.N. and V.O. are employed by Fujirebio Iberia, S.L.

**References**

1. Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s Dement 2018;14:535–562.
2. Toledo JB, Bjerke M, Da X, et al. Nonlinear association between cerebrospinal fluid and florbetapir F-18 β-amyloid measures across the spectrum of Alzheimer disease. JAMA Neurol 2015;4283:1–11.
3. Hansson O, Seibyl J, Stomrud E, et al. CSF biomarkers of Alzheimer’s disease concord with amyloid-β PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimer’s Dement 2018;14:1470–1481.
4. Schindler SE, Gray JD, Gordon BA, et al. Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimer’s Dement 2018;14:1460–1469.
5. Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 2009;65:176–183.
6. Illán-Gala I, Pegoeroles J, Montal V, et al. Challenges associated with biomarker-based classification systems for Alzheimer’s disease. Alzheimer’s Dement 2018;10:346–357.
7. Janelidze S, Zetterberg H, Mattsson N, et al. CSF Ab42/Ab40 and Ab42/Ab38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol 2016;3:154–165.
8. Janelidze S, Pannee J, Mikulskis A, et al. Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment. JAMA Neurol 2017;74:1492–1501.
9. Lewczuk P, Matzen A, Blennow K, et al. Cerebrospinal fluid Ab42/40 corresponds better than Ab42 to amyloid PET in Alzheimer’s disease. J Alzheimers Dis 2017;55:813–822.
10. Kuhlmann J, Andreasson U, Pannee J, et al. CSF Aβ1–42 – an excellent but complicated Alzheimer’s biomarker – a route to standardisation. Clin Chim Acta 2017;467:27–33.
11. Alcolea D, Carmona-Iragui M, Suárez-Calvet M, et al. Relationship between β-secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer’s disease. J Alzheimers Dis 2014;42:157–167.
12. Alcolea D, Vilaplana E, Pegueroles J, et al. Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer’s disease. Neurobiol Aging 2015;36:2018–2023.
13. Carmona-Iragui M, Fernández-Arcos A, Alcolea D, et al. Cerebrospinal fluid anti-amyloid-β autoantibodies and amyloid PET in cerebral amyloid angiopathy-related inflammation. J Alzheimer’s Dis 2015;50:1–7.
14. Alcolea D, Vilaplana E, Suárez-Calvet M, et al. CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration. Neurology 2017;89:178–188.
15. Carmona-Iragui M, Balasa M, Benejam B, et al. Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer’s disease. Alzheimer’s Dement 2017;13:1251–1260.
16. Rieck JR, Rodrigue KM, Kennedy KM, et al. The effect of beta-amyloid on face processing in young and old adults: a multivariate analysis of the BOLD signal. Hum Brain Mapp 2015;36:2514–2526.
17. Landau SM, Mintun MA, Joshi AD, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012;72:578–586.
18. Bjørke M, Portelius E, Minthon L, et al. Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis 2010;2010:1–11.
19. Hansson O, Mikulskis A, Fagan AM, et al. The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer’s disease diagnosis: a review. Alzheimer’s Dement 2018;14:1313–1333.
20. Bartlett JW, Frost C, Mattsson N, et al. Determining cut-points for Alzheimer’s disease biomarkers: statistical issues, methods and challenges. Biomark Med 2012;6:391–400.
21. Lleó A, Irwin DJ, Illán-Gala I, et al. A 2-step cerebrospinal algorithm for the selection of frontotemporal lobar degeneration subtypes. JAMA Neurol 2018;75:738–745.
22. Pannee J, Portelius E, Minthon L, et al. Reference measurement procedure for CSF amyloid beta (Aβ1–42 and the CSF Aβ1–42/Aβ1–40 ratio - a cross-validation study against amyloid PET. J Neurochem 2016;139:651–658.
23. Niemantsverdriet E, Ottoy J, Somers C, et al. The cerebrospinal fluid AB1–42/AB1–40 ratio improves concordance with amyloid-PET for diagnosing Alzheimer’s disease in a clinical setting. J Alzheimer’s Dis 2017;60:561–576.
24. Wiltfang J, Esselmann H, Bibl M, et al. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J Neurochem 2007;101:1053–1059.
25. Dumurgier J, Schraen S, Gabelle A, et al. Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study. Alzheimer’s Res Ther 2015;7.
26. Gervaise-Henry C, Watfa G, Albuisson E, et al. Cerebrospinal fluid Aβ42/Aβ40 as a means to limiting tube- and storage-dependent pre-analytical variability in clinical setting. J Alzheimers Dis 2017;57:437–445.
27. Toombs J, Foiani MS, Wellington H, et al. Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios. Alzheimer’s Dement 2018;10:311–321.
28. Delaby C, Muñoz L, Torres S, et al. Impact of CSF storage volume on the analysis of Alzheimer’s disease biomarkers on an automated platform. Clin Chim Acta 2019;490:98–101.

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Figure S1. Interassay coefficients of Aβ1-42 (A), Aβ1-40 (B), tTau (C) and pTau (D).

Figure S2. Agreement of visual amyloid PET with the combination of two CSF biomarkers or ratios.